Document:

EX-4.9

 Exhibit 4.9 

AMENDMENT TO CONVERTIBLE PROMISSORY NOTES AND WARRANTS 

This Amendment to Convertible Promissory Notes and Warrants (this “Amendment”) is made and entered into as of
January 19, 2016, by and among Exagen Diagnostics, Inc., a Delaware corporation (the “Company”) and the parties listed on the signature pages hereto. 

RECITALS 

WHEREAS, the Company has sold and issued certain Convertible Promissory Notes (each, a
“Note” and collectively, the “Notes”) to note holders (the “Note Holders”) pursuant to (i) that certain Note Purchase Agreement,
dated as of February 19, 2015, by and among the Company and the entities and persons on the Schedule of Investors attached thereto (as the same may be amended from time to time) (each such Note issued pursuant to such agreement, as amended, a
“February Note,” and collectively, the “February Notes”), (ii) that certain Note Purchase Agreement, dated as of July 2, 2015, by and among the Company and the entities and
persons on the Schedule of Investors attached thereto (as the same may be amended from time to time) (each such Note issued pursuant to such Agreement, as amended, a “July Note” and collectively, the
“July Notes”) and (iii) that certain Note and Warrant Purchase Agreement (the “October Purchase Agreement”), dated as of October 9, 2015, by and among the Company
and the entities and persons on the Schedule of Investors attached thereto (as the same may be amended from time to time) (each such Note issued pursuant to the October Purchase Agreement, an “October Note” and
collectively, the “October Notes”); 
 WHEREAS, the Company has sold and issued
certain Warrants to warrant holders (the “Warrant Holders,” and together with the Note Holders, the “Holders”) pursuant to the October Purchase Agreement (the “Warrants”); 

WHEREAS, on or about the date hereof, the Company will complete an equity financing (the
“Series E Financing”), pursuant to which the Company will sell and certain of the Holders will purchase shares of the Company’s Series E Preferred Stock, par value $0.001 per share (the “Series E
Preferred”); 
 WHEREAS, pursuant to the terms of the Notes and the Warrants, the Notes
may be converted at the option of the Majority in Interest (as defined in the Notes) into equity securities sold by the Company in a Qualified Equity Financing (as defined in the Notes), and the Warrants shall be exercisable for shares of New
Preferred Stock (as defined in the Warrants) in the event of a Qualified Equity Financing (as defined in the Warrants), with the Exercise Price (as defined in the Warrants) equal to the lowest price per share paid by investors for the equity
securities sold in the Qualified Equity Financing and used to calculate the number of shares issuable upon exercise of the Warrants; 

WHEREAS, pursuant to Section 7(b) of each of the February Notes, the February Notes may be amended
with the written consent of the Company and the holders of February Notes representing more than 50% of the aggregate outstanding principal amount of the February Notes (the “February Requisite Holders”); 

 WHEREAS, pursuant to Section 7(b) of each of the July
Notes, the July Notes may be amended with the written consent of the Company and the holders of July Notes representing more than 50% of the aggregate outstanding principal amount of the July Notes (the “July Requisite
Holders”); 
 WHEREAS, pursuant to Section 7(b) of each of the October Notes, the
October Notes may be amended with the written consent of the Company and the holders of October Notes representing more than 50% of the aggregate outstanding principal amount of the October Notes (the “October Requisite
Holders”); 
 WHEREAS, pursuant to the Section 11 of each Warrant, the Warrants may
be amended and the observance of any term thereof may be waived with the written consent of the Company and the holders of a majority in interest of the Shares (as defined in the Warrants) issuable upon exercise of the Warrants (the
“Requisite Warrant Holders,” and together with the February Requisite Holders, the July Requisite Holders and the October Requisite Holders, the “Requisite Holders”); 

WHEREAS, notwithstanding the definition of Qualified Equity Financing in the Notes and the Warrants, the
Company and the Requisite Holders desire to deem the Series E Financing to be a Qualified Equity Financing under the Notes and Warrants and amend the definition thereof in the Notes and Warrants such that upon the closing of the Series E Financing,
the Notes will be converted into shares of the Series E Preferred, and the Warrants shall be exercisable for shares of Series E Preferred; and 

WHEREAS, the undersigned Holders collectively constitute the Requisite Holders. 

NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth herein,
and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto, intending to be legally bound, agree as follows: 

ARTICLE I 
 AMENDMENT OF
NOTES 
 1.1 Section 4(b)(i) of February Notes. Section 4(b)(i) of the February Notes is hereby amended and restated in
its entirety as follows: 
 “(i) In the event the Company completes an equity financing which results in aggregate gross
proceeds to the Company of at least Five Million Dollars ($5,000,000), excluding the conversion of the Notes, and in which investors purchase shares of a newly authorized series of the Company’s Preferred Stock (a “Qualified Equity
Financing”), the Issue Price plus all accrued and previously unpaid interest thereon shall be converted into that number of fully paid and nonassessable shares of the newly authorized series of the Company’s Preferred Stock sold in
the Qualified Equity Financing (the “New Equity Shares”) as is equal to the Issue Price plus all accrued and previously unpaid interest thereon divided by the lowest price per share paid by investors for the New Equity Shares
in the Qualified Equity Financing.” 

  
 2 

 1.2 Section 4(b)(i) of July Notes. Section 4(b)(i) of the July Notes is hereby
amended and restated in its entirety as follows: 
 “(i) In the event the Company completes an equity financing which
results in aggregate gross proceeds to the Company of at least Five Million Dollars ($5,000,000), excluding the conversion of the Notes, and in which investors purchase shares of a newly authorized series of the Company’s Preferred Stock (a
“Qualified Equity Financing”), the Issue Price plus all accrued and previously unpaid interest thereon shall be converted into that number of fully paid and nonassessable shares of the newly authorized series of
the Company’s Preferred Stock sold in the Qualified Equity Financing (the “New Equity Shares”) as is equal to the Issue Price plus all accrued and previously unpaid interest thereon divided by the lowest
price per share paid by investors for the New Equity Shares in the Qualified Equity Financing.” 
 1.3 Section 4(b)(ii) of
October Notes. Section 4(b)(ii) of the October Notes is hereby amended and restated in its entirety as follows: 

“(ii) In the event the Company completes an equity financing which results in aggregate gross proceeds to the Company of
at least Five Million Dollars ($5,000,000), excluding the conversion of the Notes, and in which investors purchase shares of a newly authorized series of the Company’s Preferred Stock (a “Qualified Equity
Financing”), the Issue Price plus all accrued and previously unpaid interest thereon shall be converted into that number of fully paid and nonassessable shares of the newly authorized series of the Company’s Preferred Stock
sold in the Qualified Equity Financing (the “New Equity Shares”) as is equal to the Issue Price plus all accrued and previously unpaid interest thereon divided by the lowest price per share paid by investors for
the New Equity Shares in the Qualified Equity Financing.” 
 ARTICLE II 

AMENDMENT OF WARRANTS 

2.1 Section 2.2.1 of Warrants. The second full paragraph of Section 2.2.1 of the Warrants is hereby amended and restated in
its entirety as follows: 
 “The term “Qualified Equity Financing” shall mean an
equity financing after the date hereof which results in aggregate gross proceeds to the Company of at least Five Million Dollars ($5,000,000), excluding the conversion of the Notes, and in which investors purchase shares of a newly authorized series
of the Company’s Preferred Stock and in which the Notes are converted into Shares.” 

  
 3 

 2.2 Section 7.3 of Warrants. Section 7.3 of the Warrants is hereby amended and
restated in its entirety as follows: 
 “7.3 Effect of Certain Events and Transactions. 

(a) If this Warrant shall not have been exercised in full before the expiration of the Exercise Period, then this Warrant shall
be automatically exercised, without further action on the part of the Holder, in full (and the Holder shall be deemed to have become a holder of the Shares issuable upon such automatic exercise) on and as of the date on which the Exercise Period is
scheduled to expire unless, either (i) at any time before the expiration of the Exercise Period, the Holder shall notify the Company in writing that no such automatic exercise is to occur or (ii) the fair market value per share of the
Company’s capital stock of the same class and series as the Shares as of the time immediately preceding the expiration of the Exercise Period is less than the Exercise Price then in effect. Unless the Holder otherwise notifies the Company in
writing or the fair market value per share of the Company’s capital stock of the same class and series as the Shares as of the time immediately preceding the expiration of the Exercise Period is less than the Exercise Price then in effect, the
Holder shall be deemed to have elected to pay the Exercise Price due in connection with such automatic exercise pursuant to this Section 7(a) pursuant to the provisions of Section 2.6. If the Holder has advised the Company in writing
before the Expiration Date that no automatic exercise under this Section 7.3(a) is to occur or if the fair market value per share of the Company’s capital stock of the same class and series as the Shares as of the time immediately
preceding the expiration of the Exercise Period is less than the Exercise Price then in effect, then this Warrant shall become void, and all rights to exercise the unexercised portion of this Warrant and all rights in respect of such unexercised
portion of this Warrant shall cease immediately after expiration of the Exercise Period. 
 (b) If there shall be a
Liquidation (as defined in the Company’s certificate of incorporation, as amended and/or restated from time to time) of the Company while this Warrant remains outstanding pursuant to which the price per share to be paid or distributed for or in
respect of shares of the Company’s capital stock of the same class and series as the Shares is less than the Exercise Price in effect at the time immediately preceding the consummation of such Liquidation and such consideration is in the form
of all cash and/or marketable securities, then this Warrant shall automatically terminate as of the time immediately following the consummation of such Liquidation. 

(c) Except as is provided in Section 7.3(d), in the event of a Liquidation of the Company while this Warrant remains
outstanding pursuant to which the per share price to be paid or distributed for or in respect of shares of the Company’s capital stock of the same class and series as the Shares is greater than the Exercise Price in effect at the time
immediately preceding the consummation of such Liquidation and such consideration is in the form of all cash and/or marketable securities, the Holder may by written notice to the Company (an “Election Notice”) either: 

(i) give notice of its intent to exercise this Warrant in advance of such Liquidation (and may condition such exercise on the
consummation of such 

  
 4 

 
Liquidation) by returning the Form of Notice of Exercise or Form of Net Issue Election Notice, as applicable, annexed hereto duly executed by or on behalf of such Registered Holder; or 

(ii) in lieu of exercising this Warrant in advance of such Liquidation and receiving the consideration which the holder of the
Shares issuable on such conversion of this Warrant would receive in connection with such Liquidation Event (the “Event Consideration”), surrender this Warrant for cancellation and receive, in redemption of and in exchange for this
Warrant, an amount equal to the difference between (i) the Event Consideration with respect to the Shares for which this Warrant is exercisable immediately prior to the consummation of such Liquidation, minus (ii) the aggregate Exercise
Price of the Shares for which this Warrant was exercisable immediately prior to the consummation of such Liquidation (the “Net Warrant Event Consideration”). 

(d) If, in connection with such Liquidation, the price per share to be paid or distributed for or in respect of shares of the
Company’s capital stock of the same class and series as the Shares is greater than the Exercise Price in effect at the time of immediately preceding the consummation of such Liquidation, such consideration is in the form of all cash and/or
marketable securities and the Holder has not, prior to the time immediately preceding the consummation of such Liquidation, provided a Form of Notice of Exercise or Form of Net Issue Election Notice, then (x) the Holder shall be deemed to have
elected to surrender this Warrant for cancellation and to receive, in redemption of and in exchange for this Warrant, an amount equal to the Net Warrant Event Consideration, and (y) this Warrant shall be terminated and of no further force
immediately after the consummation of such Liquidation other than as evidence the Holder’s right to receive the Net Warrant Event Consideration. In lieu of the foregoing, the Company may provide in the definitive agreements governing such
Liquidation that the Holder shall be entitled receive an amount equal to the Net Warrant Event Consideration in exchange for and upon surrender of this Warrant.” 

2.3 Section 11 of the Warrants. Section 11 of the Warrants is hereby amended and restated in its entirety as follows: 

“11. Amendments and Waivers. This Warrant may be amended and the observance of any other term of this Warrant may
be waived (either generally or in a particular instance and either retroactively or prospectively), with the written consent of the Company and the holders of a majority in interest of the Shares issuable upon exercise of the Warrants issued
pursuant to the Purchase Agreement; provided, that: (a) any such amendment, waiver or consent shall apply with equal force to all of the Warrants issued pursuant to the Purchase Agreement and the holders of such Warrants; (b) except for
any amendment, waiver or consent which applies with equal force to all of the Warrants issued pursuant to the Purchase Agreement and the holders of such Warrants with respect to the operation of any of the provisions of such Warrants that require an
adjustment to the Exercise Price and the number and kind of shares of stock or other securities or property deliverable upon the exercise of this Warrant upon the occurrence of any specified event, transaction, condition or circumstance, the written

  
 5 

 
consent of the Holder shall be required for any amendment, waiver or consent that would (i) increase the Exercise Price or decrease the number or type of shares of stock or other securities
or property purchasable at the time of such amendment, waiver or consent upon exercise of this Warrant, or (ii) impair the Holder’s right to exercise this Warrant or the effect of Section 7.3; and (c) no consideration or other
accommodation is paid or provided to any holder of such Warrants in connection with or related to such amendment, waiver or consent that is not also offered to the Holder. Any amendment or waiver effected in accordance with this Section 11
shall be binding upon Holder of this Warrant (and of any Shares into which this Warrant is exercisable), and each future holder of all such securities and the Company.” 

2.4 New Section 14 Added to the Warrants. The following provision is added as a new Section 14 to the Warrants. 

“14. Certain Notices. If at any time: 

(a) The Company shall declare any cash dividend upon its Shares; 

(b) There shall be any acquisition or capital reorganization or reclassification of the capital stock of the Company; 

(c) There shall be a voluntary or involuntary dissolution, liquidation or winding-up of the Company; or 

(d) There shall be an initial public offering of the Company’s securities; 

then, in any one or more of said cases, the Company shall give, by first class mail, postage prepaid or by reputable overnight
express courier (charges prepaid) or by facsimile (with confirmation of transmittal) or electronic mail, addressed to the Holder of this Warrant at the address of such Holder as shown on the signature page hereof (or such other address as the Holder
may designate by advance written notice to the Company), (a) at least ten (10) days prior written notice of the date on which the books of the Company shall close or a record shall be taken for such dividend or for determining rights to
vote in respect of any such acquisition, reorganization, reclassification, dissolution, liquidation, winding-up or public offering, and (b) in the case of any such acquisition, reorganization, reclassification, dissolution, liquidation,
winding-up or public offering, at least ten (10) days prior written notice of the date when the same shall take place; provided, however, that the Holder shall make a best efforts attempt to respond to such notice as early as possible after the
receipt thereof. Any notice given in accordance with the foregoing clause (a) shall also specify, in the case of any such dividend, the date on which the holders of Shares shall be entitled thereto. Any notice given in accordance with the
foregoing clause (b) shall also specify the date on which the holders of Shares shall be entitled to exchange their Shares for securities or other property deliverable upon such acquisition, reorganization, reclassification, dissolution,
liquidation, winding-up, conversion or public offering, as the case may be.” 

  
 6 

 ARTICLE III 

MISCELLANEOUS 
 3.1
Captions. The headings contained in this Amendment are for reference purposes only and shall not affect in any way the meaning or interpretation of this Amendment. Except as otherwise indicated, all references in this Amendment to
“Sections” are intended to refer to the Sections of each Note or Warrant, as applicable. 
 3.2 Governing Law. This
Amendment and all acts and transactions pursuant hereto and the rights and obligations of the parties hereto shall be governed, construed and interpreted in accordance with the laws of the State of Delaware, without giving effect to principles of
conflicts of law. 
 3.3 Counterparts. This Amendment may be executed in counterparts, each of which shall be deemed to be an
original, and all of which together shall be deemed to be one and the same instrument. 
 3.4 Electronic and Facsimile Signatures.
Any signature page delivered electronically or by facsimile (including without limitation transmission by .pdf) shall be binding to the same extent as an original signature page, with regard to any agreement subject to the terms hereof or any
amendment thereto. Any party who delivers such a signature page agrees to later deliver an original counterpart to the other party if so requested. 

[Signature Pages Follow] 

  
 7 

 IN WITNESS WHEREOF, the parties have executed this Amendment to Convertible Promissory Notes and
Warrants as of the date first written above. 
  

			
	THE COMPANY:
	
	EXAGEN DIAGNOSTICS, INC.
		
	By:	 	 /s/ Fortunato Ron Rocca

	Name:	 	Fortunato Ron Rocca
	Title:	 	President and Chief Executive Officer

 
			
		
	Address:	 	1261 Liberty Way, Suite C
		 	Vista, CA 92081

 EXAGEN DIAGNOSTICS, INC. 

AMENDMENT TO CONVERTIBLE PROMISSORY NOTES AND
WARRANTS 
 COUNTERPART SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties have executed this Amendment to Convertible Promissory Notes and
Warrants as of the date first written above. 
  

			
	 REQUISITE HOLDER:

	
	 NMSIC FOCUSED LLC

		
	By:	 	NMSIC Co-Investment Fund LP, its sole member
	By:	 	Sun Mountain Capital Partners LLC, its General Partner
		
	By:	 	 /s/ Brian Birk

	Name:	 	Brian Birk
	Title:	 	Managing Member
		
	By:	 	 /s/ Lee Rand

	Name:	 	Lee Rand
	Title:	 	Managing Member

 
			
		
	Address:	 	Sun Mountain Capital LLC
	 	527 Don Gaspar
	 	Santa Fe, NM 87505
	 	Facsimile No.: (505) 954-5403

 EXAGEN DIAGNOSTICS, INC. 

AMENDMENT TO CONVERTIBLE PROMISSORY NOTES AND
WARRANTS 
 COUNTERPART SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties have executed this Amendment to Convertible Promissory Notes and
Warrants as of the date first written above. 
  

			
	REQUISITE HOLDER:
	
	HUNT HOLDINGS, LIMITED PARTNERSHIP
	By:	 	HuntVest, LLC, its General Partner
	By:	 	Hunt Guaranty Inc., its Sole Member
		
	By:	 	 /s/ Matthew Hunt

	Name:	 	Matthew D. Hunt
	Title:	 	Managing Partner

 
			
		
	                   Address:	 	4401 N. Mesa St.
		 	El Paso, TX 79902
		 	Facsimile No.: (915) 533-6150

 EXAGEN DIAGNOSTICS, INC. 

AMENDMENT TO CONVERTIBLE PROMISSORY NOTES AND
WARRANTS 
 COUNTERPART SIGNATURE PAGE 

 IN WITNESS WHEREOF, the parties have executed this Amendment to Convertible Promissory Notes and
Warrants as of the date first written above. 
  

			
	REQUISITE HOLDER:
	
	TULLIS-DICKERSON CAPITAL FOCUS III, L.P.
	 By:
	 	Tullis-Dickerson Partners III, L.L.C., its General Partner
		
	 By:
	 	 /s/ James L.L. Tullis

	 Name:
	 	James L.L. Tullis
	 Title:
	 	Manager

 
			
		
	 Address:
	 	500 West Putnam Avenue
		 	Suite 400
		 	Greenwich, CT 06830
		 	Facsimile No.: (561) 200-3600
	
	TULLIS-GROWTH FUND, L.P.

 
			
	 By:
	 	Tullis-Growth Partners, L.L.C., its
		 	General Partner
		
	 By:
	 	 /s/ James L.L. Tullis

	 Name:
	 	James L.L. Tullis
	 Title:
	 	Manager

 
			
		
	 Address:
	 	500 West Putnam Avenue
		 	Suite 400
		 	Greenwich, CT 06830
		 	Facsimile No.: (561) 200-3600

 EXAGEN DIAGNOSTICS, INC. 

AMENDMENT TO CONVERTIBLE PROMISSORY NOTES AND
WARRANTS 
 COUNTERPART SIGNATURE PAGEEX-4.10

 Exhibit 4.10 

THIS WARRANT AND THE SECURITIES ISSUABLE UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES
ACT”), OR ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED IN THE ABSENCE OF A REGISTRATION STATEMENT IN EFFECT WITH RESPECT TO THE SECURITIES UNDER THE SECURITIES ACT OR AN
OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED OR UNLESS SOLD PURSUANT TO AN EXEMPTION TO THE SECURITIES ACT. 

THE SALE OF THE SECURITIES WHICH ARE THE SUBJECT OF THIS WARRANT HAS NOT BEEN QUALIFIED WITH THE COMMISSIONER OF CORPORATIONS OF THE STATE OF CALIFORNIA OR
ANY OTHER STATE AND THE ISSUANCE OF SUCH SECURITIES OR THE PAYMENT OR RECEIPT OF ANY PART OF THE CONSIDERATION FOR SUCH SECURITIES PRIOR TO SUCH QUALIFICATION IS UNLAWFUL, UNLESS THE SALE OF SUCH SECURITIES IS EXEMPT FROM QUALIFICATION BY SECTION
2511, 25102 OR 25105 OF THE CALIFORNIA CORPORATIONS CODE OR SUCH PROVISIONS OF THE CORPORATIONS CODE OF ANY SUCH OTHER STATE. THE RIGHTS OF THE HOLDER OF THIS WARRANT ARE EXPRESSLY CONDITIONED UPON SUCH QUALIFICATION BEING OBTAINED, UNLESS THE SALE
IS SO EXEMPT. 
 Warrant No. 
 EXAGEN
DIAGNOSTICS, INC. 
 COMMON STOCK PURCHASE WARRANT 

THIS CERTIFIES that, for value received,
                                    , together with is
permitted successors and assigns (the “Holder”) is entitled, upon the terms and subject to the conditions hereinafter set forth, at any time on or after the date of this warrant (this “Warrant”) and on or prior to
                    , 2026 (the “Expiration Date”), but not thereafter, to subscribe for and purchase from Exagen
Diagnostics, Inc., a Delaware corporation (the “Company”),
                                    
(                    ) shares of Common Stock in the Company (the “Shares”) at an exercise price of $0.01 per share (the
“Exercise Price”), subject to adjustment as provided herein. This Warrant is one of a series of warrants issued pursuant to that certain Series E Preferred Stock Purchase and Exchange Agreement dated January 19, 2016, by and
among the Company and the entities and persons listed on the Schedules thereto (the “Purchase Agreement”), and the Holder and the Company shall be bound by all the terms, conditions and provisions of the Purchase Agreement. 

1. Exercise of Warrant. 

(a) Unless earlier terminated under Section 7, the purchase rights represented by this Warrant to purchase Shares are exercisable, in
whole or in part, before the close of business on the Expiration Date, by the surrender of this Warrant and the Notice of Exercise annexed hereto duly executed at the principal executive office of the Company (or such other

  
 1 

 
office or agency of the Company as it may designate by notice in writing to the Holder at the address of the Holder appearing on the books of the Company), and upon payment of the Exercise Price
of the Shares thereby purchased (by cash or by check or bank draft payable to the order of the Company in an amount equal to the Exercise Price of the shares thereby purchased). 

(b) Unless earlier terminated under Section 7, in lieu of exercising this Warrant by payment of cash or check pursuant to
Section 1(a), the Holder may elect to receive Shares equal to the value of this Warrant (or the portion thereof being exercised), by surrender of this Warrant at the principal executive office of the Company, together with the Notice of
Conversion annexed hereto, in which event the Company will issue to the Holder Shares in accordance with the following formula: 
  

					
		 	X =	 	Y (A-B)
		 		 	      A
			
	Where,        	 	X  =	 	the number of Shares to be issued to Holder;
			
		 	Y  =	 	the number of Shares for which the Warrant is being exercised;
			
		 	A  =	 	the fair market value of one Share; and
			
		 	B  =	 	the Exercise Price.

 For purposes of this Section 1(b), the fair market value of a Share shall be the price per Share that the
Company could obtain from a willing buyer for Shares sold by the Company from authorized but unissued Shares, as such price shall be determined in good faith by the Company’s Board of Directors. If the Shares are traded on the over-the-counter
market or on an exchange, the fair market value of a Share shall be the average of the closing bid and asked prices of Shares quoted in the over-the-counter market in which the Shares are traded or the closing price quoted on any exchange on which
the Shares are listed, whichever is applicable, as published in the Western Edition of The Wall Street Journal for the ten (10) trading days prior to the date of determination of fair market value (or such shorter period of time during which
such stock was traded over-the-counter or on such exchange). 
 (c) As soon as practicable after the exercise of this Warrant in whole or in
part, and in any event within ten (10) days thereafter, the Company at its expense will cause to be issued in the name of, and delivered to, the Holder, or such other name as specified on the Notice of Exercise delivered to the Company: 

(i) a certificate or certificates for the number of Shares to which such Holder shall be entitled; and 

(ii) in case such exercise is in part only, a Warrant or Warrants (dated the date hereof) of like tenor, calling in the aggregate on the face
or faces thereof for the number of Shares equal (without giving effect to any adjustments therein) to the number of Shares called for on the face of this Warrant minus the number of such Shares purchased by the Holder upon such exercise as provide
in Sections 1(a) or (b) above. 

  
 2 

 2. Shares to be Fully Paid; Reservation of Shares . The Company covenants that all Shares
which may be issued upon the exercise of rights represented by this Warrant will, upon issuance, be duly authorized, validly issued, fully paid and nonassessable and free from all preemptive rights of any stockholder and free from all taxes, liens
and charges in respect of the issue thereof. Certificates for Shares purchased hereunder shall be delivered to the Holder within a reasonable time after the date on which this Warrant shall have been exercised as aforesaid. The Company further
covenants and agrees that during the period within which the rights represented by this Warrant may be exercised, the Company will at all times have authorized and reserved (or will have provided for the ability to accomplish the same through a
voting contract amongst sufficient stockholders), for the purpose of issue or transfer upon exercise of the subscription rights evidenced by this Warrant, a sufficient number of shares of authorized but unissued Shares, or other securities and
property, when and as required for the exercise of the rights represented by this Warrant. 
 3. Adjustment of Exercise Price and Number
of Shares . The Exercise Price and the number of shares purchasable upon the exercise of this Warrant shall be subject to adjustment from time to time upon the occurrence of certain events described in this Section 3. Whenever the number of
Shares purchasable upon the exercise of this Warrant is adjusted as herein provided the Exercise Price payable upon exercise of this Warrant shall be adjusted by multiplying the Exercise Price in effect immediately prior to such adjustment by a
fraction, of which the numerator shall be the number of Shares purchasable upon the exercise of this Warrant immediately prior to such adjustment, and of which the denominator shall be the number of Shares so purchasable immediately thereafter. 

(a) Split, Subdivision or Combination of Shares. If the Company at any time while this Warrant, or any portion hereof, remains
outstanding and unexpired shall split, subdivide or combine the Shares, into a different number of securities of the same class, the number of Shares purchasable upon exercise of this Warrant immediately prior thereto shall be adjusted so that the
holder of this Warrant shall be entitled to receive the kind and number of Shares or other securities of the Company which the Holder would have owned or have been entitled to receive after the happening of any of the events described above, had
this Warrant been exercised immediately prior to the happening of such event or any record date with respect thereto. An adjustment made pursuant to this Section 3(a) shall become effective immediately after the effective date of such event
retroactive to the record date, if any, for such event. 
 (b) Reclassification. If the Company, at any time while this Warrant, or
any portion hereof, remains outstanding and unexpired by reclassification of securities or otherwise, shall change the Shares into the same or a different number of securities or any other class or classes, this Warrant shall thereafter represent
the right to receive the kind and number of Shares or other securities of the Company which the Holder would have owned or have been entitled to receive after the happening of the event described above, had this Warrant been exercised immediately
prior to the happening of such event or any record date with respect thereto. An adjustment made pursuant to this Section 3(b) shall become effective immediately after the effective date of such event retroactive to the record date, if any, for
such event. 
 (c) Cash Distributions. No adjustment on account of cash dividends or interest on the Shares will be made to the
Exercise Price under this Warrant. 

  
 3 

 (d) De Minimus Adjustments. No adjustment in the number of Shares purchasable hereunder
shall be required unless such adjustment would require an increase or decrease of at least one percent (1%) in the number of Shares purchasable upon the exercise of this Warrant; provided, however, that any adjustments which by reason of this
Section 3(d) are not required to be made shall be carried forward and taken into account in any subsequent adjustment. All calculations shall be made to the nearest one-thousandth of a cent and to the nearest one-hundredth of a Share, as the
case may be. 
 (e) Notice of Adjustment. Upon any adjustment of the Exercise Price or any increase or decrease in the number of
shares purchasable upon the exercise of this Warrant, the Company shall give written notice thereof, by first class mail postage prepaid or by reputable overnight express courier (charges prepaid) or by facsimile (with confirmation of transmittal)
or electronic mail, addressed to the registered Holder of this Warrant at the address of such Holder as shown on the signature page hereof (or such other address as the Holder may designate by advance written notice to the Company). The notice shall
be signed by the Company’s chief financial officer and shall state the Exercise Price resulting from such adjustment and the increase or decrease, if any, in the number of shares purchasable at such price upon the exercise of this Warrant,
setting forth in reasonable detail the method of calculation and the facts upon which such calculation is based. 
 (f) Other
Notices. If at any time: 
 (i) The Company shall declare any cash dividend upon its Shares; 

(ii) There shall be any acquisition or capital reorganization or reclassification of the capital stock of the Company; 

(iii) There shall be a voluntary or involuntary dissolution, liquidation or winding-up of the Company; or 

(iv) There shall be an initial public offering of the Company’s securities; 

then, in any one or more of said cases, the Company shall give, by first class mail, postage prepaid or by reputable overnight express courier (charges
prepaid) or by facsimile (with confirmation of transmittal) or electronic mail, addressed to the Holder of this Warrant at the address of such Holder as shown on the signature page hereof (or such other address as the Holder may designate by advance
written notice to the Company), (a) at least ten (10) days prior written notice of the date on which the books of the Company shall close or a record shall be taken for such dividend or for determining rights to vote in respect of any such
acquisition, reorganization, reclassification, dissolution, liquidation, winding-up or public offering, and (b) in the case of any such acquisition, reorganization, reclassification, dissolution, liquidation, winding-up or public offering, at
least ten (10) days prior written notice of the date when the same shall take place; provided, however, that the Holder shall make a best efforts attempt to respond to such notice as early as possible after the receipt thereof. Any notice given
in accordance 

  
 4 

 
with the foregoing clause (a) shall also specify, in the case of any such dividend, the date on which the holders of Shares shall be entitled thereto. Any notice given in accordance with the
foregoing clause (b) shall also specify the date on which the holders of Shares shall be entitled to exchange their Shares for securities or other property deliverable upon such acquisition, reorganization, reclassification, dissolution,
liquidation, winding-up, conversion or public offering, as the case may be. 
 4. No Fractional Shares or Scrip. No fractional shares
or scrip representing fractional shares shall be issued upon the exercise of this Warrant. With respect to any fraction of a share called for upon the exercise of this Warrant, an amount equal to such fraction multiplied by the then current price at
which each Share may be purchased hereunder shall be paid in cash to the Holder. 
 5. Charges, Taxes and Expenses. Issuance of
certificates for Shares upon the exercise of this Warrant shall be made without charge to the Holder hereof for any issue or transfer tax or other incidental expense in respect of the issuance of such certificate, all of which taxes and expenses
shall be paid by the Company, and such certificates shall be issued in the name of the Holder or such other name as specified on the Notice of Exercise delivered to the Company. 

6. No Rights as Stockholders. This Warrant does not entitle the Holder to any voting rights or other rights as a stockholder of the
Company prior to the exercise thereof. 
 7. Effect of Certain Events and Transactions. 

(a) If this Warrant shall not have been exercised in full before the Expiration Date, then this Warrant shall be automatically exercised,
without further action on the part of the Holder, in full (and the Holder shall be deemed to have become a holder of the Shares issuable upon such automatic exercise) on and as of the date on which the Expiration Date is scheduled to occur unless,
at any time before the Expiration Date, the Holder shall notify the Company in writing that no such automatic exercise is to occur. Unless the Holder otherwise notifies the Company in writing, the Holder shall be deemed to have elected to pay the
Exercise Price due in connection with such automatic exercise pursuant to this Section 7(a) pursuant to the provisions of Section 1(b). If the Holder has advised the Company in writing before the Expiration Date that no automatic exercise
under this Section 4(c) is to occur, then this Warrant shall become void, and all rights to exercise the unexercised portion of this Warrant and all rights in respect of such unexercised portion of this Warrant shall cease immediately after the
Expiration Date. 
 (b) If there shall be a Liquidation (as defined in the Company’s certificate of incorporation, as amended and/or
restated from time to time) of the Company while this Warrant remains outstanding pursuant to which the price per share to be paid or distributed for or in respect of shares of the Company’s capital stock of the same class and series as the
Shares is less than the Exercise Price in effect at the time immediately preceding the consummation of such Liquidation and such consideration is in the form of all cash and/or marketable securities, then this Warrant shall automatically terminate
as of the time immediately following the consummation of such Liquidation. 
 (c) Except as is provided in Section 7(d), in the event
of a Liquidation of the Company while this Warrant remains outstanding pursuant to which the per share price to be 

  
 5 

 
paid or distributed for or in respect of shares of the Company’s capital stock of the same class and series as the Shares is greater than the Exercise Price in effect at the time immediately
preceding the consummation of such Liquation and such consideration is in the form of all cash and/or marketable securities, the Holder may by written notice to the Company (an “Election Notice”) either: 

(i) give notice of its intent to exercise this Warrant in advance of such Liquidation (and may condition such exercise on the consummation of
such Liquidation) by returning the Notice of Exercise annexed hereto duly executed by or on behalf of such Registered Holder; or 
 (ii) in
lieu of exercising this Warrant in advance of such Liquidation and receiving the consideration which the holder of the Shares issuable on such conversion of this Warrant would receive in connection with such Liquidation Event (the “Event
Consideration”), surrender this Warrant for cancellation and receive, in redemption of and in exchange for this Warrant, an amount equal to the difference between (i) the Event Consideration with respect to the Shares for which this
Warrant is exercisable immediately prior to the consummation of such Liquidation, minus (ii) the aggregate Exercise Price of the Shares for which this Warrant was exercisable immediately prior to the consummation of such Liquidation (the
“Net Warrant Event Consideration”). 
 (d) If, in connection with such Liquidation, the price per share to be paid or
distributed for or in respect of shares of the Company’s capital stock of the same class and series as the Shares is greater than the Exercise Price in effect at the time of immediately preceding the consummation of such Liquidation, such
consideration is in the form of all cash and/or marketable securities and the Holder has not, prior to the time immediately preceding the consummation of such Liquidation, provided an Election Notice, then (x) the Holder shall be deemed to have
elected to surrender this Warrant for cancellation and to receive, in redemption of and in exchange for this Warrant, an amount equal to the Net Warrant Event Consideration, and (y) this Warrant shall be terminated and of no further force
immediately after the consummation of such Liquidation other than as evidence the Holder’s right to receive the Net Warrant Event Consideration. In lieu of the foregoing, the Company may provide in the definitive agreements governing such
Liquidation that the Holder shall be entitled receive an amount equal to the Net Warrant Event Consideration in exchange for and upon surrender of this Warrant. 

8. Loss, Theft, Destruction or Mutilation of Warrant. Upon receipt by the Company of evidence reasonably satisfactory to it of the
loss, theft, destruction or mutilation of this Warrant, and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it, and upon reimbursement to the Company of all reasonable expenses incidental thereto, and upon
surrender and cancellation of this Warrant, if mutilated, the Company will make and deliver a new warrant of like tenor and dated as of such cancellation, in lieu of this Warrant. 

  
 6 

 9. Miscellaneous. 

(a) Issue Date. The provisions of this Warrant shall be construed and shall be given effect in all respects as if this Warrant had been
issued and delivered by the Company on the date set forth below. 
 (b) Governing Law. THIS WARRANT SHALL BE GOVERNED BY, AND
CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF DELAWARE WITHOUT REGARD TO CONFLICTS OF LAWS PRINCIPLES. 
 (c) Restrictions.
By acceptance hereof, the Holder acknowledges that the Shares acquired upon the exercise of this Warrant may have restrictions upon their resale imposed by state and federal securities laws, and that certain Fifth Amended and Restated
Stockholders’ Agreement, as it may be amended from time to time. 
 (d) Saturdays, Sundays, Holidays, etc. If the last or
appointed day for the taking of any action or the expiration of any right required or granted herein shall be a Saturday or a Sunday or shall be a legal holiday, then such action may be taken or such right may be exercised on the next succeeding day
not a Saturday, Sunday or legal holiday. 
 (e) Waivers and Amendments. This Warrant may be amended and the observance of any other
term of this Warrant may be waived (either generally or in a particular instance and either retroactively or prospectively), with the written consent of the Company and the holders of 55% of the Shares issuable upon exercise of the Warrants issued
pursuant to the Purchase Agreement; provided, that: (i) any such amendment, waiver or consent shall apply with equal force to all of the Warrants issued pursuant to the Purchase Agreement and the holders of such Warrants; (ii) except for
any amendment, waiver or consent which applies with equal force to all of the Warrants issued pursuant to the Purchase Agreement and the holders of such Warrants with respect to the operation of any of the provisions of such Warrants that require an
adjustment to the Exercise Price and the number and kind of shares of stock or other securities or property deliverable upon the exercise of this Warrant upon the occurrence of any specified event, transaction, condition or circumstance, the written
consent of the Holder shall be required for any amendment, waiver or consent that would (x) increase the Exercise Price or decrease the number or type of shares of stock or other securities or property purchasable at the time of such amendment,
waiver or consent upon exercise of this Warrant, or (y) impair the Holder’s right to exercise this Warrant or the effect of Section 7; and (iii) no consideration or other accommodation is paid or provided to any holder of such
Warrants in connection with or related to such amendment, waiver or consent that is not also offered to the Holder. Any amendment or waiver effected in accordance with this Section 9(e) shall be binding upon Holder of this Warrant (and of any
Shares into which this Warrant is exercisable), and each future holder of all such securities and the Company. 
 (f) Assignment.
This Warrant may be assigned or transferred by the Holder only with the prior written approval of the Company. 
 [SIGNATURE
PAGE FOLLOWS] 

  
 7 

 IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto
duly authorized. 
  

					
	Date: ______________, 2016	 	EXAGEN DIAGNOSTICS, INC.
		 	a Delaware corporation
			
		 	By:	 	  

		 	Name:	 	Fortunato Ron Rocca
		 	Title:	 	Chief Executive Officer
		
		 	 Address:        1261 Liberty Way

		 		 	          Vista, CA 92081

  

			
	ACKNOWLEDGED AND AGREED:
	
	[NAME OF HOLDER]
		
	 By:
	 	  

	 Name:
	 	  

	 Title:
	 	
 

			
		
	 Address:
	 	  

		 	  

	 Facsimile No.:
	 	  

 EXAGEN DIAGNOSTICS, INC. 

WARRANT TO PURCHASE SHARES OF 

COMMON STOCK 

 NOTICE OF EXERCISE 

 

	TO:	Exagen Diagnostics, Inc. 

	  	1261 Liberty Way 

	  	Vista, CA 92081 

	  	ATTN: Secretary 

 1. The undersigned hereby elects to purchase
                     shares of Common Stock (the “Shares”) of Exagen Diagnostics, Inc. pursuant to the terms of the attached
Warrant, and makes payment in the form of (check applicable box or boxes): 
  ̈
$                     in lawful money of the United States; and/or 

 ̈ the cancellation of such portion of the attached Warrant as is exercisable for a total of
                     Warrant Shares (using a fair market value of
$                     per share for purposes of this calculation); and/or 

 ̈ the cancellation of such number of Shares as is necessary, in accordance with the formula
set forth in subsection 1(b), to exercise this Warrant with respect to the maximum number of Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 1(b). 

2. Please issue a certificate or certificates representing the Shares in the name of the undersigned or in such other name as is specified
below: 
  

			
	 	 	  

	 	 	(Print Name)
		
		 	Address:                                   
                  
		
		 	  

 3. The undersigned confirms that the Shares are being acquired for the account of the undersigned for
investment only and not with a view to, or for resale in connection with, the distribution thereof and that the undersigned has no present intention of distributing or selling the Shares. [THIS PROVISION TO BE REMOVED IN THE EVENT OF EXERCISE IN
CONNECTION WITH A LIQUIDATION] 
  

					
	  
	 		 	  

	(Date)	 		 	(Signature)
			
		 		 	  

		 		 	(Print Name)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00254-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00254-of-00352.parquet"}]]